Navigation Links
ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
Date:10/28/2010

dney, on (+612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.  

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Web site.ResMed Inc and SubsidiariesCondensed Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)Three Months Ended

September 30,2010

2009Net revenue

$282,012

$246,992Cost of sales

108,058

96,814Gross profit

173,954

150,178Operating expensesSelling, general and administrative

84,791

76,756Research and development

19,739

17,914Amortization of acquired intangible assets

2,030

1,845Donation to Foundation

1,000

1,000Total operating expenses

107,560

97,515Income from operations

66,394

52,663Other income, net:Interest income, net

5,097

2,125Other, net

5,063

3,118Total other income, net

10,160

5,243Income before income taxes

76,554

57,906Income taxes

19,846

15,804Net income

$56,708

$42,102Basic earnings per share

$0.37

$0.28Diluted earnings per share

$0.36

$0.27Basic shar
'/>"/>

SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
2. Study Shows ResMeds New CPAP Device Increases Patient Compliance
3. ResMed Inc. Announces Completion of Two-for-One Stock Split
4. ResMed Announces Deferred Conversions in Connection With Stock Split
5. ResMed Inc. to Present at Upcoming Conferences
6. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
8. ResMed Acquires Laboratoires Narval
9. Jazz Pharmaceuticals Announces November 4 Conference Call to Discuss Third Quarter 2010 Results and Guidance
10. BioMarin Announces Third Quarter 2010 Financial Results
11. IRIDEX Announces Third Quarter 2010 Conference Call and Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ANDOVER, Mass. , Oct. 1, 2014 /PRNewswire/ ... ; AEX: PHIA) today announced its eCareCoordinator and ... the U.S. Food and Drug Administration (FDA). A ... of telehealth programs , eCareCoordinator and eCareCompanion are ... are the first clinical applications to be available ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... Calif., Sept. 19, 2011 Amgen (NASDAQ: ... Drug Administration (FDA) approved two new indications for Prolia® ... women at high risk for fracture receiving adjuvant aromatase ... to increase bone mass in men at high risk ...
... Sept. 19, 2011 Boston Scientific Corporation (NYSE: ... a highly deliverable and ultra-low profile 0.014 inch balloon ... procedures below the knee.  The Company has begun marketing ... markets.   Boston Scientific developed the Coyote ...
Cached Medicine Technology:FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 2FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 3FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 4FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 5FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 6FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 7FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 8Boston Scientific Launches Coyote™ Balloon Catheter 2Boston Scientific Launches Coyote™ Balloon Catheter 3Boston Scientific Launches Coyote™ Balloon Catheter 4
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Join the more than 80 golfers who already ... ever charity golf tournament to benefit Project HEAL, a not-for-profit ... cannot afford treatment. The tournament will be held Monday, Oct. ... , The day-long event starts with 10:30 a.m. check-in and ... will begin at 5 p.m. and will include an auction ...
(Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
(Date:10/1/2014)... Today in Bahir Dar, Ethiopia, at the occasion ... has gathered some 150 African and international leishmaniasis ... treatment safety and efficacy monitoring plan, carried ... Kenya, Sudan, Uganda, and Ethiopia, were presented to ... access to treatment of kala-azar with the combination ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... helps people who cannot swallow because of paralysis. Swallowing is ... of the cranial nerves. One of these, the vagal nerve, ... tract// - that is, above the esophagus, but below the ... to the lungs, and swallowing difficulties may occur. ...
... a huge men population, which evaluated more than 14,000 sperm ... reducing their numbers as well as their crucial ability to ... as the ozone level went up, the sperm concentration went ... and obstetrics and gynecology at the University of Southern California's ...
... long-awaited treatment for lymphoma - a drug that uses ... cells. Idec Pharmaceuticals' Zevalin becomes the first radioimmunotherapy drug ... ,It's a new approach, adding radiation to antibodies that ... cells. The antibodies attach to the cells, flagging them ...
... that helps form blood clots, may also be involved in ... to new strategies for repairing diseases of the nervous system, ... on the basic science level.// ,In multiple sclerosis, the ... fibers in the brain and spine can lead to numbness, ...
... According to a new study, filtering out the antibodies that ... with live donor transplants. Many patients need a kidney transplant ... found. Body organs, from dead bodies, are in short supply, ... they must be of a compatible blood group. ...
... the symptoms of Lyme disease linger despite antibiotic treatment.,Lyme ... ticks, sometimes produces very long-lasting fatigue and cognitive problems. ... feel that this treatment would not be enough to ... Lyme patients, some of whom were assigned to the ...
Cached Medicine News:Health News:Elevated Ozone Levels Hurt Sperm Count 2Health News:Clotting Protein plays a role in nerve repair 2
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Coronary angiographic catheter...
Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
Medicine Products: